Shareholders are referred to the cautionary announcement released by Aspen on 4 February 2013 (and subsequent renewals of this cautionary announcement) in which shareholders were advised of discussions between Aspen and MSD, known as Merck in the United States and Canada, in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient facility situated primarily in the Netherlands and a related portfolio of pharmaceutical finished dose form products.
These discussions remain ongoing and may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen’s securities.
Durban
3 June 2013
